文献速递免疫规划妇幼与学校卫生

泰国孕妇接种Tdap疫苗的反应原性及母体与脐带血清中百日咳博德特菌抗体评估

Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
PubMed 文献 · Vaccine · 2018-01-01

研究纳入370名18-40岁泰国孕妇,于妊娠26-36周接种Tdap疫苗(Boostrix®),通过电话随访和病历回顾评估不良事件,并用酶联免疫吸附试验定量检测分娩时母体及脐带血中抗百日咳毒素、丝状血凝素和百日咳杆菌粘附素的IgG。结果显示,既往含破伤风类毒素疫苗接种未影响Tdap疫苗的反应原性,分娩前至少8周接种可使所有研究的百日咳博德特菌抗原抗体滴度处于高水平。

要点

  • 370名孕妇于妊娠26-36周接种Tdap疫苗,既往含破伤风类毒素疫苗接种未影响反应原性。
  • 分娩前至少8周接种Tdap疫苗,对全部研究的百日咳博德特菌抗原均产生高抗体滴度。
  • 脐带血中高滴度抗百日咳博德特菌抗体提示抗体经胎盘转移,可能有助于保护新生儿早期免受百日咳侵袭。

核心结论

  • 妊娠期接种Tdap疫苗的反应原性不受既往破伤风类毒素免疫影响。
  • 脐带血中高滴度抗百日咳博德特菌抗体提供了抗体转移的证据,应有助于保护新生儿早期免受百日咳侵袭。

研究设计与样本

  • 研究纳入370名18-40岁孕妇,于妊娠26-36周接种Tdap疫苗(Boostrix®,葛兰素史克,比利时里克森萨特)。
  • 通过电话随访和病历回顾识别接种后不良事件。
  • 采用酶联免疫吸附试验(EUROIMMUN®,德国吕贝克)定量检测分娩时母体及脐带血中抗百日咳毒素、抗丝状血凝素和抗百日咳杆菌粘附素IgG。

主要发现

  • 在过去五年内额外接种含破伤风疫苗(N=181)或本次妊娠期间接种多剂含破伤风疫苗(N=98)的孕妇中,未报告不良事件严重程度或持续时间增加。
  • 分娩前至少8周接种疫苗可使所有研究的百日咳博德特菌抗原抗体滴度处于高水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pregnant Thai women have low antibody titers against B. pertussis antigens, which coincide with an increasing incidence of pertussis among Thai infants. Thus, there exists a potential benefit of a booster dose of tetanus- diphtheria-acellular pertussis (Tdap) vaccine administered during pregnancy. Here, we report the vaccine reactogenicity profile and birth outcomes in Tdap-vaccinated pregnant women who have or have not had prior immunization with tetanus vaccine, and the IgG levels to B. pertussis antigens in maternal and cord sera at delivery. MATERIALS AND METHODS: Pregnant women (N = 370) aged 18-40 years were administered the Tdap vaccine (Boostrix®, GlaxoSmithKline, Rixensart, Belgium) at 26-36 weeks gestation. Adverse events following vaccination were identified by follow-up telephone call and medical record review. IgG against pertussis toxin (anti-PT), filamentous hemagglutinin (anti-FHA) and pertactin (anti-PRN) in both maternal and umbilical cord blood obtained at delivery were quantitatively evaluated using enzyme-linked immunosorbent assay (EUROIMMUN®, Lübeck, Germany). RESULTS: There was no reported increase in the severity or duration of adverse events associated with the administration of an extra tetanus-containing vaccine within the previous five years (N = 181) or multiple doses of tetanus-containing vaccines during the current pregnancy (N = 98). Vaccination at least eight weeks prior to delivery resulted in high antibody titers to all B. pertussis antigens studied. CONCLUSIONS: The reactogenicity of Tdap vaccine administered during pregnancy was not affected by prior tetanus toxoid immunization. High transplacental antibody against B. pertussis antigens in the cord blood provides evidence of antibody transfer and should thus help to protect newborns from pertussis during early life.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wanlapakorn N, Maertens K, Chaithongwongwatthana S, et al. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women. Vaccine. 2018. PMID: 29426663. doi:10.1016/j.vaccine.2018.01.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。